ES2742442T3 - Compuestos inhibidores - Google Patents

Compuestos inhibidores Download PDF

Info

Publication number
ES2742442T3
ES2742442T3 ES17192253T ES17192253T ES2742442T3 ES 2742442 T3 ES2742442 T3 ES 2742442T3 ES 17192253 T ES17192253 T ES 17192253T ES 17192253 T ES17192253 T ES 17192253T ES 2742442 T3 ES2742442 T3 ES 2742442T3
Authority
ES
Spain
Prior art keywords
alkyl
methyl
methoxy
pyrimidin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17192253T
Other languages
English (en)
Spanish (es)
Inventor
Swen Hoelder
Julian Blagg
Savade Solanki
Hannah Woodward
Sebastien Naud
Vassilios Bavetsias
Peter Sheldrake
Paolo Innocenti
Kwai-Ming J Cheung
Butrus Atrash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Application granted granted Critical
Publication of ES2742442T3 publication Critical patent/ES2742442T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES17192253T 2012-09-07 2013-09-09 Compuestos inhibidores Active ES2742442T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1216017.2A GB201216017D0 (en) 2012-09-07 2012-09-07 Inhibitor compounds

Publications (1)

Publication Number Publication Date
ES2742442T3 true ES2742442T3 (es) 2020-02-14

Family

ID=47137117

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17192253T Active ES2742442T3 (es) 2012-09-07 2013-09-09 Compuestos inhibidores
ES13760106.8T Active ES2655194T3 (es) 2012-09-07 2013-09-09 Compuestos inhibidores

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13760106.8T Active ES2655194T3 (es) 2012-09-07 2013-09-09 Compuestos inhibidores

Country Status (22)

Country Link
US (6) US9409907B2 (https=)
EP (2) EP2892889B1 (https=)
JP (2) JP6216791B2 (https=)
CN (1) CN104837829B (https=)
AU (2) AU2013311434B2 (https=)
BR (1) BR112015004489B1 (https=)
CA (1) CA2884006C (https=)
CY (1) CY1119714T1 (https=)
DK (2) DK2892889T3 (https=)
ES (2) ES2742442T3 (https=)
GB (1) GB201216017D0 (https=)
HR (1) HRP20171835T1 (https=)
HU (1) HUE036259T2 (https=)
LT (1) LT2892889T (https=)
NO (1) NO2892889T3 (https=)
PL (1) PL2892889T3 (https=)
PT (1) PT2892889T (https=)
RS (1) RS56750B1 (https=)
RU (1) RU2673079C2 (https=)
SI (1) SI2892889T1 (https=)
SM (1) SMT201700596T1 (https=)
WO (1) WO2014037750A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
EP3231804B1 (en) 2008-03-21 2021-03-03 The General Hospital Corporation Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
BR112016005199B1 (pt) 2013-08-23 2022-02-22 Neupharma, Inc Certos compostos químicos, composições, e métodos
GB201403536D0 (en) * 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
JP6616934B2 (ja) * 2014-05-22 2019-12-04 株式会社 資生堂 レナリドミドの光学分割方法
EP3270694A4 (en) * 2015-02-17 2018-09-05 Neupharma, Inc. Certain chemical entities, compositions, and methods
ES2966392T3 (es) 2015-04-17 2024-04-22 Crossfire Oncology Holding B V Biomarcadores pronósticos para quimioterapia inhibidora de TTK
SG11201709837RA (en) 2015-05-29 2017-12-28 Teijin Pharma Ltd PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
WO2017012559A1 (zh) * 2015-07-21 2017-01-26 广州再极医药科技有限公司 稠环嘧啶类化合物、中间体、其制备方法、组合物和应用
GB201522532D0 (en) * 2015-12-21 2016-02-03 Cancer Rec Tech Ltd Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
WO2018035061A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
HUE053220T2 (hu) 2016-11-28 2021-06-28 Teijin Pharma Ltd ((Piridin-2-il)-amino)pirido[3,4-d]pirimidin és ((piridazin-3-il)-amino)pirido[3,4-d]pirimidin származékok mint CDK4/6 inhibitorok pl. reumatoid artritisz, érelmeszesedés, tüdõfibrózis, agyi infartus vagy rák kezelésére
PE20191133A1 (es) 2016-11-28 2019-09-02 Teijin Pharma Ltd Cristal de derivado de pirido[3,4-d]pirimidina o su solvato
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
EP3641745A1 (en) * 2017-06-20 2020-04-29 The Institute of Cancer Research : The Royal Cancer Hospital Methods and medical uses
US11175469B2 (en) 2017-10-26 2021-11-16 CommScope Connectivity Belgium BVBA Telecommunications system
GB201809458D0 (en) * 2018-06-08 2018-07-25 Crt Pioneer Fund Lp Salt form
GB201809460D0 (en) 2018-06-08 2018-07-25 Crt Pioneer Fund Lp Salt form
JP7601869B2 (ja) 2019-10-30 2024-12-17 ▲勁▼方医▲薬▼科技(上海)有限公司 置換された複素環-環系化合物、その調製方法及び医薬への応用
KR102396930B1 (ko) * 2020-01-15 2022-05-12 한국과학기술연구원 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물
TW202140473A (zh) * 2020-01-15 2021-11-01 美商纜圖藥品公司 Map4k1抑制劑
TW202202498A (zh) * 2020-07-01 2022-01-16 大陸商四川海思科製藥有限公司 一種並環雜環衍生物及其在醫藥上的應用
JP2023533855A (ja) * 2020-07-16 2023-08-04 ダーマヴァント サイエンシーズ ゲーエムベーハー イソキノリン化合物およびそのAhR不均衡の治療への使用
CN115942937B (zh) * 2020-08-17 2025-07-25 浙江扬厉医药技术有限公司 嘧啶并环类化合物
IL302807A (en) 2020-11-18 2023-07-01 Deciphera Pharmaceuticals Llc Gcn2 and perk kinase inhibitors and methods of use thereof
CN115583946B (zh) * 2021-07-06 2026-01-16 赛诺哈勃药业(成都)有限公司 杂环化合物及其作为cdk抑制剂的用途
AU2022412837A1 (en) * 2021-12-16 2024-06-13 Teijin Pharma Limited Cdk9 inhibitor and use thereof
CN121548580A (zh) * 2023-05-15 2026-02-17 亚历克西亚治疗公司 Cdk抑制剂化合物
WO2025038785A1 (en) * 2023-08-16 2025-02-20 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions, and therapeutic applications
CN117800875B (zh) * 2023-12-21 2024-10-22 泰州精英化成医药科技有限公司 一种反式-(N-Boc-4-氨基环己基)乙酸的制备方法
WO2025155740A1 (en) * 2024-01-17 2025-07-24 Iambic Therapeutics, Inc. Combinations comprising aza-quinazoline compounds for use in the treatment of cancer

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2697710A (en) 1953-01-02 1954-12-21 Burroughs Wellcome Co Pyrido (2,3-d) pyrimidines and method of preparing same
US3021332A (en) 1954-01-04 1962-02-13 Burroughs Wellcome Co Pyrido (2, 3-d) pyrimidine compounds and method of making
PL181893B1 (pl) 1994-11-14 2001-10-31 Warner Lambert Co Zwiazki bedace pochodnymi pirymidyny i naftyrydyny oraz preparat farmaceutyczny zawierajacy je PL PL PL
US7053070B2 (en) 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
CA2397961C (en) 2000-01-25 2008-08-26 Richard John Booth Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
AU6118001A (en) 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
WO2002090360A1 (en) 2001-05-10 2002-11-14 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2003000011A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
JP2005516927A (ja) 2001-12-13 2005-06-09 アボット・ラボラトリーズ 癌治療用のキナーゼ阻害剤としての3−(フェニル−アルコキシ)−5−(フェニル)−ピリジン誘導体および関連化合物
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
ES2314224T3 (es) 2002-03-07 2009-03-16 F. Hoffmann-La Roche Ag Inhibidores pirimidina y piridina biciclicos de p38 quinasa.
AU2003251661A1 (en) * 2002-08-06 2004-02-25 F. Hoffmann-La Roche Ag 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
AU2003291329A1 (en) 2002-11-12 2004-06-03 Abbott Laboratories Bicyclic-substituted amines as histamine-3 receptor ligands
US20040092521A1 (en) 2002-11-12 2004-05-13 Altenbach Robert J. Bicyclic-substituted amines as histamine-3 receptor ligands
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
US20050256118A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
CN101213187B (zh) 2005-06-28 2012-06-06 塞诺菲-安万特股份有限公司 作为rho-激酶抑制剂的异喹啉衍生物
US7910595B2 (en) * 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
JP2010514693A (ja) * 2006-12-22 2010-05-06 ノバルティス アーゲー Pdk1阻害のためのキナゾリン
WO2008135232A1 (en) 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
AU2008296479A1 (en) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
JPWO2009084695A1 (ja) * 2007-12-28 2011-05-19 カルナバイオサイエンス株式会社 2−アミノキナゾリン誘導体
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン, エルエルシー 複素環式化合物およびその使用
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
GB201011182D0 (en) 2010-07-02 2010-08-18 Wireless Fibre Systems Ltd Riser wireless communications system
ES2539972T3 (es) * 2010-07-30 2015-07-07 Nerviano Medical Sciences S.R.L. Isoxazolo-quinazolinas como moduladores de la actividad de proteina cinasa
ES2377610B1 (es) 2010-09-01 2013-02-05 Institut Químic de Sarriá CETS Fundació Privada Preparación de compuestos pirido[2,3-d]pirimidin-7(8h)-ona sustituidos.
US9394290B2 (en) 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ, インコーポレイテッド 複素環化合物及びその使用
EA026115B1 (ru) 2010-12-17 2017-03-31 Ф. Хоффманн-Ля Рош Аг Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение
US8987271B2 (en) 2010-12-22 2015-03-24 Eutropics Pharmaceuticals, Inc. 2,2′-biphenazine compounds and methods useful for treating disease
WO2012092471A2 (en) 2010-12-29 2012-07-05 Development Center For Biotechnology Novel tubulin inhibitors and methods of using the same
EP2668190B1 (en) * 2011-01-26 2016-08-17 Nerviano Medical Sciences S.r.l. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US9745191B2 (en) 2011-04-11 2017-08-29 Saudi Arabian Oil Company Auto thermal reforming (ATR) catalytic structures
CA2843417C (en) 2011-07-29 2018-08-21 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer
US20140051679A1 (en) 2011-10-12 2014-02-20 Univeristy Health Networks Kinase inhibitors and method of treating cancer with same
GB201216017D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
WO2014134169A1 (en) 2013-02-26 2014-09-04 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
EP3089747A1 (en) 2013-12-06 2016-11-09 F. Hoffmann-La Roche AG Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
BR112016020897A2 (en) 2014-03-11 2018-01-23 The Council Of The Queensland Institute Of Medical Research Determination of cancer aggressiveness, prognosis, and responsiveness to treatment
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
WO2016073771A2 (en) 2014-11-06 2016-05-12 Ohio State Innovation Foundation Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
GB201522532D0 (en) 2015-12-21 2016-02-03 Cancer Rec Tech Ltd Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
EP3641745A1 (en) 2017-06-20 2020-04-29 The Institute of Cancer Research : The Royal Cancer Hospital Methods and medical uses

Also Published As

Publication number Publication date
JP6216791B2 (ja) 2017-10-18
PL2892889T3 (pl) 2018-03-30
RU2015112580A (ru) 2016-10-27
US20200165241A1 (en) 2020-05-28
US20180141944A1 (en) 2018-05-24
EP2892889A1 (en) 2015-07-15
AU2013311434A1 (en) 2015-04-02
WO2014037750A1 (en) 2014-03-13
US9409907B2 (en) 2016-08-09
US20150239884A1 (en) 2015-08-27
BR112015004489A2 (pt) 2017-07-04
SMT201700596T1 (it) 2018-01-11
CA2884006A1 (en) 2014-03-13
NO2892889T3 (https=) 2018-03-17
CA2884006C (en) 2021-01-19
JP2015527387A (ja) 2015-09-17
EP3293183A1 (en) 2018-03-14
HUE036259T2 (hu) 2018-06-28
GB201216017D0 (en) 2012-10-24
RS56750B1 (sr) 2018-03-30
RU2673079C2 (ru) 2018-11-22
ES2655194T3 (es) 2018-02-19
US9890157B2 (en) 2018-02-13
EP3293183B1 (en) 2019-07-24
JP2018027967A (ja) 2018-02-22
US11046688B2 (en) 2021-06-29
CY1119714T1 (el) 2018-06-27
DK3293183T3 (da) 2019-08-12
HRP20171835T1 (hr) 2017-12-29
JP6496376B2 (ja) 2019-04-03
HK1211921A1 (en) 2016-06-03
PT2892889T (pt) 2018-01-09
EP2892889B1 (en) 2017-10-18
SI2892889T1 (sl) 2017-12-29
LT2892889T (lt) 2017-12-11
US20160220570A1 (en) 2016-08-04
BR112015004489B1 (pt) 2020-09-29
CN104837829A (zh) 2015-08-12
US20220402912A1 (en) 2022-12-22
CN104837829B (zh) 2019-07-05
US10479788B2 (en) 2019-11-19
AU2017268488A1 (en) 2017-12-14
AU2013311434B2 (en) 2017-10-19
US9834552B2 (en) 2017-12-05
DK2892889T3 (en) 2017-12-11
US20160222009A1 (en) 2016-08-04
AU2017268488B2 (en) 2019-06-13
US11897877B2 (en) 2024-02-13

Similar Documents

Publication Publication Date Title
ES2742442T3 (es) Compuestos inhibidores
US11555036B2 (en) FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof
US11591326B2 (en) Inhibitors of protein arginine methyltransferase 5 (PRMT5), pharmaceutical products thereof, and methods thereof
CN109195972B (zh) 作为ret激酶抑制剂的杂环化合物
WO2024032704A1 (en) Heterocyclic compounds, compositions thereof, and methods of treatment therewith
AU2010279019B2 (en) Compounds for the reduction of beta-amyloid production
ES2884030T3 (es) 2-amino-N-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-carboxamida como inhibidor de ATR quinasa
US9371319B2 (en) Pyrrolopyridineamino derivatives as MPS1 inhibitors
CA3157789A1 (en) 2-methyl-aza-quinazolines
JP6297570B2 (ja) 薬理活性化合物
ES2814289T3 (es) 1,5-Dihidro-4H-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4H-pirazolo[4,3-c]piridin-4-onas como inhibidores de la PDE1
JP6440728B2 (ja) N2−フェニル−ピリド[3,4−d]ピリミジン−2,8−ジアミン誘導体およびmps1阻害剤としてのそれらの使用
UA101676C2 (uk) Піримідинові сполуки, композиції і способи застосування
RU2515541C2 (ru) N-7 замещенные пурины и пиразолопиримидины, их композиции и способы применения
CN113968856B (zh) 一类具有激酶抑制活性的化合物
US20240417405A1 (en) Substituted Spiro Derivatives
US20250313575A1 (en) Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
ES2992772T3 (en) Benzothiazol-6-yl acetic acid derivatives and their use for treating hiv infection
HK1211921B (en) Inhibitor compounds